LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
89.43
-0.60 (-0.67%)
At close: 4:03PM EDT
Stock chart is not supported by your current browser
Previous Close90.03
Open89.83
Bid88.75 x 800
Ask90.75 x 1000
Day's Range88.87 - 89.98
52 Week Range73.69 - 89.98
Volume3,171,005
Avg. Volume3,820,693
Market Cap91.279B
Beta0.30
PE Ratio (TTM)83.58
EPS (TTM)1.07
Earnings DateJul 24, 2018
Forward Dividend & Yield2.25 (2.57%)
Ex-Dividend Date2018-08-14
1y Target Est92.59
Trade prices are not sourced from all markets
  • Study Published in The Lancet Shows Benefit of Baricitinib 4 mg for the Treatment of Systemic Lupus Erythematosus (SLE)
    PR Newswire12 hours ago

    Study Published in The Lancet Shows Benefit of Baricitinib 4 mg for the Treatment of Systemic Lupus Erythematosus (SLE)

    INDIANAPOLIS , July 19, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that results of a global systemic lupus erythematosus (SLE) Phase 2 ...

  • LLY vs. NVO: Which Stock Is the Better Value Option?
    Zacks20 hours ago

    LLY vs. NVO: Which Stock Is the Better Value Option?

    LLY vs. NVO: Which Stock Is the Better Value Option?

  • Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2?
    Zacks21 hours ago

    Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2?

    Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

  • Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study
    Zacks21 hours ago

    Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study

    Pfizer (PFE) and Eli Lilly (LLY) announce that their investigational pain candidate, tanezumab, significantly reduces pain in osteoarthritis patients.

  • Boehringer Ingelheim and Lilly announce Tradjenta's CARMELINA® cardiovascular outcome trial meets primary endpoint
    PR Newswire22 hours ago

    Boehringer Ingelheim and Lilly announce Tradjenta's CARMELINA® cardiovascular outcome trial meets primary endpoint

    RIDGEFIELD, Conn. and INDIANAPOLIS, July 19, 2018 /PRNewswire/ -- CARMELINA® (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk) met its primary endpoint, defined as time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3-point MACE), with Tradjenta® demonstrating similar cardiovascular safety compared with placebo. Boehringer Ingelheim and Eli Lilly and Company (LLY) announced the positive top-line results from the trial, which evaluated the impact of treatment with Tradjenta compared with placebo on cardiovascular safety on top of standard of care. The study included 6,979 adults with type 2 diabetes and high cardiovascular risk.

  • The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, BNY, TJX and Raytheon
    Zacks22 hours ago

    The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, BNY, TJX and Raytheon

    The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, BNY, TJX and Raytheon

  • Lilly's Once-Weekly Trulicity® (dulaglutide) Label Updated to Include Data Showing Benefits for Adults with Type 2 Diabetes and Chronic Kidney Disease
    PR Newswire23 hours ago

    Lilly's Once-Weekly Trulicity® (dulaglutide) Label Updated to Include Data Showing Benefits for Adults with Type 2 Diabetes and Chronic Kidney Disease

    INDIANAPOLIS, July 19, 2018 /PRNewswire/ -- The U.S. label for Eli Lilly and Company's (LLY) once-weekly Trulicity® (dulaglutide) is updated to show the medicine's safety and efficacy in people with type 2 diabetes who have moderate to severe chronic kidney disease (CKD). The label now includes data from the AWARD-7 clinical trial, which showed that people treated with Trulicity 1.5 mg or 0.75 mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss, compared to those treated with traditional basal-bolus insulin.1 Trulicity is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist (RA) injectable prescription medicine to improve blood sugar (glucose) in adults with type 2 diabetes.

  • Estimates and Recommendations for Eli Lilly on July 18
    Market Realist2 days ago

    Estimates and Recommendations for Eli Lilly on July 18

    Analysts expect Eli Lilly and Company (LLY) to report revenue of ~$6.1 billion during the second quarter, a 3.8% rise YoY (year-over-year) compared to $5.7 billion during the second quarter of 2017. Analysts expect its net income margin to expand to 22.5% during the second quarter compared to 20.2% during the second quarter of 2017, mainly due to a decrease in overall selling, general, and administrative expenses and a decrease in research and development expenses. Eli Lilly’s stock price has risen nearly 7.1% in the last 12 months and nearly 6.1% year-to-date.

  • MarketWatch2 days ago

    Pfizer, Eli Lilly non-opioid pain drug nears finish line

    A new non-opioid drug for osteoarthritis pain being developed by Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY) had positive early results in a phase 3 clinical trial, the companies announced on Wednesday. Patients who received two doses of the drug had a statistically significant improvement in pain, physical function and their own assessment of their osteoarthritis, relative to patients on the placebo. More information about progressive osteoarthritis seen in patients is still needed, though, said EvercoreISI analyst Umer Raffat, and the companies in particular "likely [need] longer follow up before being more definitive" about tanezumab's safety.

  • Eli Lilly’s Q2 2018 Estimates: Expect Revenue Growth
    Market Realist2 days ago

    Eli Lilly’s Q2 2018 Estimates: Expect Revenue Growth

    Wall Street analysts expect an increase of ~3.8% in Eli Lilly and Company’s (LLY) second-quarter revenue to $6.1 billion following the strong performance of its new and existing products. Since Eli Lilly’s products are sold in over 120 countries worldwide, and its international sales contribute ~44% of its total revenue, the company is exposed to currency risk, and foreign exchange is expected to have a positive impact on its overall revenue during the second quarter.

  • Top Analyst Reports for Netflix, Eli Lilly & BNY Mellon
    Zacks2 days ago

    Top Analyst Reports for Netflix, Eli Lilly & BNY Mellon

    Top Analyst Reports for Netflix, Eli Lilly & BNY Mellon

  • What to Expect from Eli Lilly and Company’s Q2 2018 Earnings
    Market Realist2 days ago

    What to Expect from Eli Lilly and Company’s Q2 2018 Earnings

    Eli Lilly is set to release its second-quarter earnings on July 24. Eli Lilly surpassed Wall Street analysts’ consensus estimates for EPS and revenue in the first quarter, reporting EPS of $1.34 on revenue of $5.7 billion. For the second quarter, analysts expect EPS of $1.30 for Eli Lilly on revenue of ~$6.0 billion.

  • Reuters2 days ago

    Pfizer-Lilly pain drug meets late-stage trial goals

    The treatment, tanezumab, belongs to an investigational category of pain medications that target nerve growth factor, a protein involved in the growth of nerve cells, and is also being evaluated to treat chronic lower back and cancer pain. U.S. regulators in 2015 lifted a hold on trials of medicines targeting the protein due to concerns they could worsen osteoarthritis in a small percentage of patients. Pfizer's shares were marginally up at $37.79 in premarket trade.

  • Reuters2 days ago

    Pfizer-Lilly pain drug meets late-stage trial goals

    An experimental osteoarthritis drug developed by Pfizer Inc and Eli Lilly and Co achieved its main goal of lowering pain in a late stage trial, the companies said on Wednesday, potentially offering a safer alternative to opioids. The treatment, tanezumab, belongs to an investigational category of pain medications that target nerve growth factor, a protein involved in the growth of nerve cells, and is also being evaluated to treat chronic lower back and cancer pain. U.S. regulators in 2015 lifted a hold on trials of medicines targeting the protein due to concerns they could worsen osteoarthritis in a small percentage of patients.

  • Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain
    Business Wire2 days ago

    Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain

    Pfizer Inc.(PFE) and Eli Lilly and Company (LLY) today announced that a 16-week Phase 3 study in patients with osteoarthritis (OA) pain evaluating subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, met all three co-primary endpoints. The study demonstrated that patients who received two doses of tanezumab separated by eight weeks experienced a statistically significant improvement in pain, physical function and the patients’ overall assessment of their OA, compared to those receiving placebo. Tanezumab is part of an investigational class of pain medications known as nerve growth factor (NGF) inhibitors and in addition to OA pain, is being evaluated for chronic low back pain (CLBP) and cancer pain (due to bone metastases).

  • Analyst Recommendations for Valeant Pharmaceuticals in July
    Market Realist4 days ago

    Analyst Recommendations for Valeant Pharmaceuticals in July

    In July, the FDA accepted Bausch + Lomb’s NDA (New Drug Application) for sub-micron loteprednol etabonate for the treatment of patients who have undergone ocular surgery and are showing symptoms of post-operative inflammation and pain.

  • J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay
    Zacks4 days ago

    J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay

    The FDA defers decision regarding label expansion application to include cardiovascular indication on the label of J&J's (JNJ) diabetes drug Invokana.

  • The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon
    Zacks4 days ago

    The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon

    The Zacks Analyst Blog Highlights: PepsiCo, Eli Lilly, Broadcom, Biogen and Marathon

  • 3 Dividend Stocks That Should Pay You the Rest of Your Life
    Motley Fool5 days ago

    3 Dividend Stocks That Should Pay You the Rest of Your Life

    These buy-and-hold dividend stocks can be counted on for income.

  • Here are Q2's 10 biggest VC-backed exits from the Bay Area
    American City Business Journals7 days ago

    Here are Q2's 10 biggest VC-backed exits from the Bay Area

    Here is a look at the 10 biggest venture-backed IPOs and acquisitions from the first half of what has been a very active year for such exits.

  • Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom
    Zacks7 days ago

    Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom

    Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom

  • Better Buy: Acadia Pharmaceuticals vs. Eli Lilly
    Motley Fool7 days ago

    Better Buy: Acadia Pharmaceuticals vs. Eli Lilly

    Which stock wins in a battle between a small, beaten-down biotech and an established major drugmaker?

  • New Lilly Diabetes helpline to Assist People Seeking Solutions to Insulin Affordability
    PR Newswire8 days ago

    New Lilly Diabetes helpline to Assist People Seeking Solutions to Insulin Affordability

    INDIANAPOLIS, July 12, 2018 /PRNewswire/ -- Starting August 1, a new dedicated helpline called the Lilly Diabetes Solution Center will assist people who need help paying for their insulin – such as those with lower incomes, the uninsured, and people in the deductible phase of their high-deductible insurance plans, Eli Lilly and Company (LLY) announced today. A customized suite of solutions for all Lilly insulins, including for Humalog® (insulin lispro), will be used by helpline operators to find answers that best fit the personal circumstances of patients.

  • The Sad Truth: This Biotech Investing Strategy Almost Always Works
    Motley Fool9 days ago

    The Sad Truth: This Biotech Investing Strategy Almost Always Works

    We want researchers to cure disease. But the honest truth is that you could potentially make a fortune by betting against drugmakers in this indication.